Eupraxia Pharmaceuticals (EPRX.TO)

Eupraxia Pharmaceuticals stock price today, ATLAS forecast and fair value

Healthcare · Biotechnology · Toronto Stock Exchange · Canada

CA$9.98▲ +4.50%

Prices as of Oct 27, 2026 · CAD

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

46%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Eupraxia Pharmaceuticals in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Eupraxia Pharmaceuticals

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Eupraxia Pharmaceuticals a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between CA$8.58 and CA$11.18; in 9 out of 10, between CA$6.78 and CA$14.14. Estimated annual volatility is 81%.

Price, last 12 months (weekly close)

Key numbers

Market cap: CA$613M
Market cap (USD): $436M
52-week high: CA$13.08
52-week low: CA$7.35
Operating margin: 0.0%
Net margin: 0.0%
Beta: 1.22

What this means

ATLAS does not publish a fair value for EPRX.TO right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks EPRX.TO has traded between CA$7.35 and CA$13.08. Today it is 23.7% below that high and 36% above its low.

Its beta is 1.22: it tends to move more than the market, both up and down.

About the company

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.

Want to see everything about Eupraxia Pharmaceuticals?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Eupraxia Pharmaceuticals do?

What is the chance EPRX.TO goes up next month?

46%: close to a coin flip. In half of the simulated outcomes, EPRX.TO ends the month between CA$8.58 and CA$11.18.

How big is Eupraxia Pharmaceuticals and what is its P/E ratio?

Eupraxia Pharmaceuticals's market capitalization is CA$613M. We do not show a P/E because it has no positive earnings to base one on.

How volatile is EPRX.TO?

ATLAS estimates annual volatility at 81%. In a typical month, half of the outcomes end between CA$8.58 and CA$11.18.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer